The Cancer Letter

Inside information on cancer research and drug development

In Brief

Kids V Cancer named one of top 10 most innovative companies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

KIDS V CANCER was named as one of Fast Company’s Top 10 Most Innovative Companies of 2016 in Not-For-Profit, placing fourth. Fast Company praised Kids v Cancer for accelerating the discovery of pediatric cancer treatments.

Other organizations in this category include Black Lives Matter, 92nd St Y, Humans Of New York and UNICEF. Last year, Kids v Cancer received the 2015 Peter F. Drucker Award for Nonprofit Innovation.

Through the Creating Hope Act, Kids v Cancer has mobilized almost $1 billion for research and development of drugs. With the valuation of a Creating Hope Act pediatric priority review voucher reaching $350 million, biotech and pharmaceutical companies are now focusing on business plans built around pediatric rare disease drug development.

Table of Contents

YOU MAY BE INTERESTED IN

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
By Matthew Bin Han Ong
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account